For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 312,779 | 188,138* | 209,933 | 194,179 |
| Acquired manufacturing rights | - | 0* | - | - |
| General and administrative | 33,071 | 32,639* | 32,447 | 32,040 |
| Total operating expenses | 345,850 | 220,776 | 242,380 | 226,219 |
| Loss from operations | -345,850 | -220,776* | -242,380 | -226,219 |
| Interest income | 26,610 | 29,220* | 29,259 | 31,073 |
| Other income (expense) | -1,382 | -5,967* | 291 | 28,573 |
| Total other income, net | 25,228 | 23,253* | 29,550 | 59,646 |
| Net loss | -320,622 | -197,523 | -212,830 | -166,573 |
| Basic EPS | -2.3 | -1.452 | -1.56 | -1.22 |
| Diluted EPS | -2.3 | -1.452 | -1.56 | -1.22 |
| Basic Average Shares | 139,506,680 | 136,038,260 | 136,196,512 | 136,033,746 |
| Diluted Average Shares | 139,506,680 | 136,038,260 | 136,196,512 | 136,033,746 |
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)